More than four decades on from the approval of the first biologic drug, the industry has reached a tipping point, and biotech drugs now outnumber small molecules in the global R&D pipeline.
Cue Biopharma Inc. has reached a preclinical milestone in its collaboration and license agreement with Boehringer Ingelheim Pharma GmbH & Co. KG, following the latter’s selection of a first compound for lead optimization. The milestone triggers a $7.5 million payment to Cue.
Researchers from the University of Naples Federico II (Italy) and collaborating institutions reportedd the design of a next-generation mRNA vaccine that leverages a phylogenetically informed consensus receptor binding domain heterotrimers representing the major variant lineages.
Researchers from Hangzhou Innogate Pharma Co. Ltd. and Innorace Biopharma Co. Ltd. have identified new cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors that are potentially useful for the treatment of Aicardi-Goutieres syndrome, psoriasis, rheumatoid arthritis, systemic lupus erythematosus and more.
Simcere Pharmaceutical Group Ltd.’s monoclonal antibody, rademikibart (CBP-201), met the primary endpoint in a Chinese phase III study in adults and adolescents with moderate to severe atopic dermatitis.
Galapagos NV is about to bury its recent turbulent past and sail off for the future with its $3 billion cash pile and the new name of Lakefront Biotherapeutics NV. The foundation for the transition was laid earlier this month in an arrangement with Gilead Sciences Inc., holder of 25% of Galapagos’ equity, to “co-parent” the assets of Ouro Medicines LLC, which Gilead is acquiring for up to $2.17 billion.
Nimbus Salacia Inc. has disclosed new serine/threonine-protein kinase SIK2 (QIK) inhibitors potentially useful for the treatment of autoimmune disease, cancer, diabetes, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis and skin hyperpigmentation, among others.
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the treatment of atopic dermatitis.
Certain cancers, such as triple-negative breast cancer, produce antibodies that, although they help fight the tumor, can cross the blood-brain barrier and alter the function of NMDA receptors (NMDAR) in the brain, which are essential for neuronal signaling. Scientists at Cold Spring Harbor Laboratory (CSHL) have identified their origin and described how this process is linked to the maturation of these antibodies, which can activate or inhibit the receptor, causing neurological and psychiatric symptoms.
Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the condition advances. Yet the biological divide between those who experience this cognitive decline and those who do not has remained an open question. Are they different conditions or simply stages of the same disease?
RSS
